Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study / Cervantes, F., Ross, D.M., Radinoff, A., Palandri, F., Myasnikov, A., Vannucchi, A.M., Zachee, P., Gisslinger, H., Komatsu, N., Foltz, L., Mannelli, F., Passamonti, F., Gilotti, G., Sadek, I., Tiwari, R., Zor, E., Al-Ali, H.K.. - In: LEUKEMIA. - ISSN 0887-6924. - ELETTRONICO. - 35:(2021), pp. 3626-3626. [10.1038/s41375-021-01396-x]
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Vannucchi, Alessandro MWriting – Original Draft Preparation
;Mannelli, Francesco;
2021
Abstract
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
